Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00056875
NCT00056875CompletedPhase 1

Safety and Efficacy of Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants

University of Michigan1 site in 1 country50 target enrollmentStarted: September 1, 2002Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
50
Locations
1
Study OverviewStudy DesignEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This is a single arm dose escalation study of recombinant human keratinocyte growth factor given to patients undergoing allogeneic bone marrow transplantation who are at high risk for graft versus host disease (GVHD).

Detailed Description

Completion date provided represents the completion date of the grant per OOPD records

Study Design

Study Type
Interventional
Allocation
Non Randomized
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
3 Years to 65 Years (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Eligible for full intensity bone marrow transplant (BMT) conditioning but who lack a 6/6 HLA idential sibling donor

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials

Terminated
Phase 1
Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHDAcute Graft Versus Host Disease
NCT00038792M.D. Anderson Cancer Center7
Completed
Phase 1
Keratinocyte Growth Factor to Prevent Acute GVHDGraft-vs-Host Disease
NCT00031148FDA Office of Orphan Products Development72
Completed
Early Phase 1
Keratinocyte Growth Factor- Hair Serum for the Prevention of Chemotherapy Induced AlopeciaChemotherapy-Induced ChangeHair LossAlopecia DrugsAlopecia
NCT04554732University of Arizona28
Completed
Phase 2
A Study of Recombinant Human Growth Hormone Injection（JINTOPIN AQ）for Short Children With Small for SGASmall for Gestational Age Infant
NCT03221933Changchun GeneScience Pharmaceutical Co., Ltd.120
Completed
Not Applicable
A study to assess the safety and the effects of using a growth factor, keratinocyte growth factor (KGF), in patients with moderate asthmaRespiratoryAsthma
ISRCTN02767559Southampton University Hospitals NHS Trust (UK)20